Previous in vitro data in ACC cell lines (11) led to the conception of a phase II clinical trial of the receptor tyrosine kinase (RTK) inhibitor sunitinib targeting VEGFR2, and PDGFRβ among others. Here, NTRK1 is linked to adrenal cortex carcinoma.